EP4671372A2 — Translation-enhancing nucleic acid compounds: ASO-coupled translation upregulation 1 (ACT-UP1) and uses thereof
Assigned to Arnatar Therapeutics Inc · Expires 2025-12-31 · 0y expired
What this patent protects
Disclosed herein are methods and compounds for enhancing gene expression by ACT-UP 1 compounds. Such methods and compounds are useful for increasing expression of certain genes, many of which are associated with a variety of diseases and disorders.
USPTO Abstract
Disclosed herein are methods and compounds for enhancing gene expression by ACT-UP 1 compounds. Such methods and compounds are useful for increasing expression of certain genes, many of which are associated with a variety of diseases and disorders.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.